Abstracts tagged "anti-TNF therapy and methotrexate (MTX)"

Abstract Number: 1823 • 2017 ACR/ARHP Annual Meeting
Methotrexate Requires High Serum BAFF Levels to Prevent Immunization Against TNF-α Inhibitors
Samuel Bitoun¹, Pierre Dönnes², Aline Doublet³, Kimberly Florence⁴, Agnes Hincelin-Mery⁵, Gaetane Nocturne⁶, Mattieu Allez⁷, N Ruperto⁸, Marc Pallardy⁹ and Xavier Mariette¹⁰, ¹INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicëtre, France, ²SciCross AB, Skövde, Sweden, ³Department of Rheumatology, Kremlin-Bicêtre hospital INSERM U1184, Le Kremlin Bicêtre, France, ⁴Immunogenicity and Clinical Immunology, GlaxoSmithKline, King of Prussia, PA, ⁵Sanofi, Chilly-Mazarin, France, ⁶INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ⁷Department of Gastroenterology, Hopital Saint-Louis, APHP, Paris, France, ⁸PRINTO Coordinating Centre, Genoa, Italy, ⁹Inflammation, Chimiokines et Immunopathologie, INSERM UMR 996, Faculté de Pharmacie, Chatenay Mallabry, France, ¹⁰Université Paris Sud, Paris, France
Background/Purpose: Immunization against TNF Inhibitors (TNFi) is observed in 30-50% of patients with inflammatory rheumatic diseases. With most TNFi, anti-drug antibodies (ADA) lead to rapid…
Abstract Number: 142 • 2015 ACR/ARHP Annual Meeting
Exploration of General Practioners’ Difficulties with Methotrexate and Anti-TNF Therapies in Routine Practice
Elise Berthet¹, Virginie Moiroud², Marion De Rosa², Martin Soubrier³ and Sylvain Mathieu⁴, ¹Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ²Médecine Générale, CHU Gabriel Montpied, Clermont-Ferrand, France, ³Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁴Rheumatology Department, CHU clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Chronic inflammatory arthritis affects around 1% of the general population. Disease-modifying drugs like methotrexate (MTX) and in second-line anti tumor necrosis factor (anti-TNF) therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].